GLP-1 and Restless Legs Syndrome: Iron, Dopamine, and Mirapex Evidence

Restless legs syndrome (RLS, also called Willis–Ekbom disease) affects roughly one in ten US adults and about 2–3% severely (Allen 2005 REST^[9]). The dominant treatable driver is iron — about half of primary RLS cases respond to iron repletion, but the ferritin target for RLS is > 75 ng/mL (Allen 2018 IRLSSG iron guideline^[2]), not the 30 ng/mL cutoff used for general iron-deficiency anemia. That matters for GLP-1 patients, because semaglutide and tirzepatide cut food intake by roughly a third during dose escalation, which mechanically reduces dietary iron at the exact moment that any pre-existing RLS is most likely to flare. The 2024–2025 treatment hierarchy has also shifted: alpha-2-delta calcium channel ligands (gabapentin enacarbil, pregabalin, gabapentin) are now first-line over dopamine agonists in most cases, because of the augmentation phenomenon (Garcia-Borreguero 2016^[3], Winkelman 2016 AAN^[4]). This article walks through the evidence and the practical protocol.

The honest summary

• RLS is common. The REST general population study (Allen 2005^[9]) reported ~10% RLS prevalence in US adults and ~2.7% with symptoms severe enough to require treatment (two or more times per week plus moderate-or-greater distress).
• Iron is the dominant treatable driver. Brain-iron deficiency — not just systemic iron deficiency — is the central pathophysiology (Connor 2003 autopsy series^[5]). The IRLSSG iron guideline (Allen 2018^[2]) targets ferritin > 75 ng/mL and transferrin saturation > 20%, and the Cochrane review (Trotti 2019^[6]) found iron supplementation improves RLS symptoms, with IV iron showing the strongest signal.
• Alpha-2-delta ligands are now first-line over dopamine agonists. Allen 2014 NEJM^[8] randomized 719 RLS patients to pregabalin 300 mg or pramipexole 0.25/0.5 mg for 52 weeks — symptom control was similar but augmentation rates were sharply higher on pramipexole. The Garcia-Borreguero 2016 combined task force^[3] and the AAN 2016 guideline (Winkelman 2016^[4]) both recommend gabapentin enacarbil (Horizant), pregabalin, or gabapentin first.
• GLP-1 hits the iron axis. Reduced food intake during dose escalation cuts dietary iron, and the common GLP-1 add-on of an oral iron supplement worsens the baseline constipation. Baseline ferritin is a cheap, high-yield test in any patient with RLS symptoms or family history. See our companion article on GLP-1 iron deficiency.

What RLS actually is — and how to recognize it

The IRLSSG 2014 diagnostic criteria (Allen 2014, Sleep Medicine^[1]) are summarized by the URGE mnemonic and require all five of the following:

• U — Urge to move the legs, typically accompanied by uncomfortable sensations (creeping, crawling, electric, deep-aching).
• R — Rest worsens it. Symptoms begin or worsen during periods of inactivity (sitting, lying down).
• G — Gets better with movement. Walking, stretching, or rubbing the legs partially or fully relieves the urge, at least while the movement continues.
• E — Evening predominance. Symptoms occur exclusively or predominantly in the evening or night.
• Not solely accounted for by another condition such as leg cramps, positional discomfort, arthritis, peripheral neuropathy, or akathisia.

Severity is graded with the International Restless Legs Scale (IRLS-RS), a 10-item validated instrument scored 0 (none) to 40 (very severe). Most published RCTs use IRLS-RS change as the primary endpoint and a 3-point change as the minimum clinically important difference.

Brain iron — the central pathophysiology

Connor 2003 (Neurology^[5]) examined post-mortem substantia nigra tissue from RLS patients and found markedly reduced iron-staining and reduced transferrin-receptor expression compared to age-matched controls — despite normal or near-normal serum ferritin. The interpretation is that RLS reflects impaired blood-brain-barrier iron transport, not necessarily whole-body iron deficiency. That is why the ferritin target for RLS treatment is > 75 ng/mL (Allen 2018 IRLSSG iron guideline^[2]), well above the > 30 ng/mL cutoff used for systemic iron-deficiency anemia. Dopamine synthesis depends on iron-containing tyrosine hydroxylase, which connects brain-iron deficiency to the long-observed symptomatic response to dopamine agonists.

The 2024–2025 treatment hierarchy

The combined Garcia-Borreguero 2016 IRLSSG/EURLSSG/RLS-Foundation task force^[3] and the AAN 2016 practice guideline (Winkelman 2016, Neurology^[4]) inverted the previous decade's ordering. The current first-line choices for symptomatic RLS are the alpha-2-delta calcium channel ligands:

• Gabapentin enacarbil (Horizant) 600 mg once daily at 5 PM. The only FDA-approved gabapentinoid for RLS, with the most predictable pharmacokinetics. Brand cost ~$400/month without coverage.
• Pregabalin (Lyrica) 75–300 mg once nightly. Generic, ~$15–30/month. Allen 2014 NEJM^[8] showed 52-week efficacy comparable to pramipexole with much lower augmentation.
• Gabapentin 300–900 mg once nightly. Generic, ~$10/month. Less predictable absorption than gabapentin enacarbil but the cheapest workable option.

Dopamine agonists — pramipexole (Mirapex), ropinirole (Requip), and rotigotine (Neupro transdermal patch) — remain effective for symptom control but are now recommended for short-term or intermittent use because of augmentation (Garcia-Borreguero 2016^[3]). They are appropriate when alpha-2-delta drugs fail, are contraindicated, or when the patient prefers transdermal dosing (rotigotine patch).

Refractory severe RLS has a published opioid option: prolonged-release oxycodone-naloxone (the RELOXYN trial, Trenkwalder 2013 Lancet Neurol^[7]) randomized 306 patients with severe RLS who had failed prior treatment and showed a mean IRLS-RS reduction of about 8 points at 12 weeks versus about 2 points on placebo. Low-dose methadone is also used in specialist settings. Both require explicit risk-benefit discussion and careful monitoring.

The iron axis — and why it matters more on a GLP-1

The Allen 2018 IRLSSG iron guideline^[2] sets out the practical algorithm:

• Check fasting ferritin and transferrin saturation at baseline in every patient with RLS symptoms.
• Oral iron 65 mg elemental once daily on an empty stomach (e.g., ferrous sulfate 325 mg) plus vitamin C 250–500 mg, taken on alternate days to maximize absorption. Continue until ferritin > 100 ng/mL and transferrin saturation > 25%.
• Intravenous iron — ferric carboxymaltose (Injectafer), iron sucrose (Venofer), or low-molecular-weight iron dextran — is indicated if oral iron fails, is not tolerated, or if symptoms are severe and the patient cannot wait the typical 8–12 weeks for oral repletion. Allen 2011^[10] showed IV ferric carboxymaltose produced clinically meaningful IRLS-RS improvement in a placebo-controlled trial. The Cochrane review (Trotti 2019^[6]) found IV iron had the strongest evidence signal across the iron formulations.

GLP-1 patients have two specific iron-axis problems. First, appetite suppression cuts total dietary intake during dose escalation by roughly 30%, which proportionally cuts dietary iron. Second, the most common GLP-1 side effect is constipation, and oral iron is famously constipating, so compliance with iron supplementation is worse than baseline. For any GLP-1 patient with RLS symptoms (or with a sister, mother, or other first-degree relative with RLS — family history confers high risk), a baseline ferritin and transferrin saturation is high-value. The companion article on GLP-1 iron deficiency and ferritin covers the broader iron picture.

Magnitude: IRLS-RS improvement at 12 weeks

The augmentation problem

Augmentation is the paradoxical worsening of RLS symptoms during chronic dopamine-agonist therapy — earlier evening onset, expansion to other body parts, increased symptom intensity. Allen 2014 NEJM^[8] randomized 719 patients to pregabalin 300 mg or pramipexole 0.25 or 0.5 mg for 52 weeks. Symptom control was similar across arms in the first weeks, but augmentation occurred in roughly 8–9% of the pramipexole arms versus roughly 2% of the pregabalin arm over 52 weeks. The Garcia-Borreguero 2016 task force^[3] recommends:

• Avoid starting a dopamine agonist as first line unless alpha-2-delta drugs are contraindicated or have failed.
• If augmentation develops, switch to a long-acting dopamine agonist (rotigotine patch) or cross-titrate to an alpha-2-delta ligand.
• Always check ferritin when symptoms worsen — iron deficiency mimics augmentation.

Drugs that make RLS worse

The standard worsening-agent list (Allen 2018^[2], Winkelman 2016^[4]) includes:

• SSRIs and SNRIs. Sertraline, fluoxetine, paroxetine, venlafaxine, and duloxetine commonly worsen RLS. If the antidepressant is essential, bupropion is the preferred alternative because it is pro-dopaminergic.
• Dopamine antagonists. Antipsychotics (haloperidol, risperidone, olanzapine) and the antiemetic metoclopramide (Reglan) and prochlorperazine (Compazine) all worsen RLS. Ondansetron (Zofran) does not.
• First-generation antihistamines. Diphenhydramine (Benadryl, ZzzQuil, the sleep ingredient in Tylenol PM) is one of the most reliable RLS-worsening drugs. Loratadine, fexofenadine, and cetirizine are acceptable substitutes.

For GLP-1 patients, the antiemetic question matters because ondansetron is the first-line nausea agent and does not worsen RLS — that is the right pick. Metoclopramide should be avoided. The GLP-1 first 30 days survival guide covers the nausea-management ladder.

The practical GLP-1 + RLS protocol

1. Baseline ferritin and transferrin saturation for any patient with RLS symptoms or first-degree family history. Order alongside the routine GLP-1-start labs (HbA1c, lipid panel, eGFR, TSH).
2. If ferritin < 75 ng/mL: start oral ferrous sulfate 325 mg (65 mg elemental iron) plus vitamin C 250–500 mg on alternate days, empty stomach if tolerated. Target ferritin > 100 ng/mL and transferrin saturation > 25%. Re-check at 8–12 weeks.
3. If ferritin < 30 ng/mL with severe RLS, or oral iron fails or is not tolerated: refer for IV ferric carboxymaltose (Injectafer) 750–1,000 mg total dose, typically over one or two infusions (Allen 2011^[10], Trotti 2019 Cochrane^[6]).
4. If pharmacotherapy is needed: start gabapentin enacarbil 600 mg at 5 PM (preferred if insurance covers Horizant), pregabalin 75–150 mg nightly, or gabapentin 300–900 mg nightly. Titrate based on response. Reserve dopamine agonists for refractory cases and use intermittently when possible (Garcia-Borreguero 2016^[3], Winkelman 2016^[4]).
5. Audit other medications. If on an SSRI or SNRI, discuss switching to bupropion with the prescriber. Stop diphenhydramine-containing sleep aids and PM analgesics. For GLP-1 nausea, use ondansetron rather than metoclopramide.
6. Re-evaluate at every dose escalation. Each GLP-1 step-up reduces food intake and can drop ferritin. Repeat ferritin at 6 months on therapy, more often if RLS symptoms recur.

Cost and insurance

Gabapentin generic is roughly $10/month at most US pharmacies; pregabalin generic is $15–30/month; pramipexole generic is ~$20/month. Brand Horizant (gabapentin enacarbil) and brand Mirapex ER are substantially more expensive ($300–500/month without coverage) and insurance coverage varies. IV ferric carboxymaltose is typically covered when ferritin is documented < 30 ng/mL and oral iron has failed; an infusion-center fee plus the drug cost runs $1,500–3,000 per session without insurance.

Related research and tools

• GLP-1 iron deficiency and ferritin — the companion piece on iron-deficiency anemia, ferritin testing intervals, and oral vs IV iron during GLP-1 therapy
• GLP-1 first 30 days survival guide — nausea-management ladder including the ondansetron-vs-metoclopramide decision relevant to RLS
• GLP-1 hair loss — shares the iron and ferritin axis; many patients present with both symptoms during dose escalation
• GLP-1 for adults age 65+ — RLS prevalence rises with age and overlaps with sarcopenia screening
• GLP-1 brain fog — daytime cognitive symptoms often trace back to fragmented sleep from unrecognized RLS
• GLP-1 + benzodiazepines — sleep-medication interactions relevant when treating RLS-driven insomnia
• GLP-1 + lithium and mood stabilizers — dopamine-antagonist medications in this class can worsen RLS
• GLP-1 side effect questions answered — the broader side-effect hub

Important disclaimer. This article is educational and does not constitute medical advice. RLS diagnosis should be confirmed by a clinician familiar with the IRLSSG criteria and the differential (peripheral neuropathy, akathisia, leg cramps). Iron supplementation — especially intravenous iron — carries non-trivial risks (anaphylactoid reactions, hypophosphatemia with ferric carboxymaltose) and should be supervised. Drug substitutions for SSRIs, SNRIs, and antiemetics should be made with the prescribing clinician, not independently. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if new RCT data on alpha-2-delta vs dopamine-agonist long-term outcomes or IV iron protocols is published.